3/24
07:23 am
ird
Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 [TheStreet.com]
Low
Report
Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 [TheStreet.com]
3/24
07:00 am
ird
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
Low
Report
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
3/16
09:00 am
ird
Opus Genetics (IRD) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $10.00 price target on the stock.
Low
Report
Opus Genetics (IRD) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $10.00 price target on the stock.
3/12
08:44 am
ird
Opus Genetics (IRD) had its price target raised by Wedbush from $8.00 to $10.00. They now have an "outperform" rating on the stock.
Medium
Report
Opus Genetics (IRD) had its price target raised by Wedbush from $8.00 to $10.00. They now have an "outperform" rating on the stock.
3/12
08:44 am
ird
Opus Genetics (IRD) had its price target raised by Chardan Capital from $9.00 to $11.00. They now have a "buy" rating on the stock.
Medium
Report
Opus Genetics (IRD) had its price target raised by Chardan Capital from $9.00 to $11.00. They now have a "buy" rating on the stock.
3/11
02:15 pm
ird
Opus Genetics (IRD) was given a new $9.00 price target by Craig Hallum. They now have a "buy" rating on the stock.
Low
Report
Opus Genetics (IRD) was given a new $9.00 price target by Craig Hallum. They now have a "buy" rating on the stock.
3/10
10:44 pm
ird
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]
3/10
07:37 am
ird
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update [Yahoo! Finance]
Low
Report
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update [Yahoo! Finance]
3/10
07:00 am
ird
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
Low
Report
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
3/3
08:13 am
ird
Opus Genetics to Present at Upcoming Investor Conferences in March 2026 [Yahoo! Finance]
Neutral
Report
Opus Genetics to Present at Upcoming Investor Conferences in March 2026 [Yahoo! Finance]
3/3
08:00 am
ird
Opus Genetics to Present at Upcoming Investor Conferences in March 2026
Neutral
Report
Opus Genetics to Present at Upcoming Investor Conferences in March 2026
3/2
08:03 am
ird
Opus Genetics (IRD) had its price target raised by BTIG Research from $7.00 to $12.00. They now have a "buy" rating on the stock.
Low
Report
Opus Genetics (IRD) had its price target raised by BTIG Research from $7.00 to $12.00. They now have a "buy" rating on the stock.
3/1
01:10 am
ird
Medium
Report
2/27
10:40 am
ird
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting [Yahoo! Finance]
High
Report
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting [Yahoo! Finance]
2/27
10:10 am
ird
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
High
Report
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
2/25
07:18 am
ird
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia [Yahoo! Finance]
Medium
Report
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia [Yahoo! Finance]
2/25
06:59 am
ird
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Medium
Report
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
2/22
09:40 pm
ird
Opus Genetics: Asymmetric Upside With LCA5 And BEST1 [Seeking Alpha]
Neutral
Report
Opus Genetics: Asymmetric Upside With LCA5 And BEST1 [Seeking Alpha]
2/13
02:48 pm
ird
Update: Opus Genetics Shares Rise After Announcement of $25 Million Private Placement [Yahoo! Finance]
Low
Report
Update: Opus Genetics Shares Rise After Announcement of $25 Million Private Placement [Yahoo! Finance]
2/13
07:30 am
ird
Opus Genetics Announces $25 Million Private Placement
Medium
Report
Opus Genetics Announces $25 Million Private Placement
2/13
06:29 am
ird
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Medium
Report
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
2/2
08:00 am
ird
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
Low
Report
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
1/28
08:04 am
ird
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.
Medium
Report
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.
1/27
07:00 am
ird
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
Low
Report
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
1/21
06:19 am
ird
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Medium
Report
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at BTIG Research to a "strong-buy" rating.